MRC1 and ovarian carcinoma: Immune checkpoint inhibitors, for instance, were expected to show promise in treating ovarian cancer, particularly in patients with tumors exhibiting MMR deficiency and/or high levels of immune cell infiltration, but results have been disappointing [57,58,59,80].